Previous 10 | Next 10 |
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced t...
Aptorum Group ( NASDAQ: APM ) announced a private offering of $3M aggregate principal amount of convertible note due 2023. The note will be solely subscribed by Aenco Technologies which is indirectly 34.56% effectively owned by Mr. Ian Huen, a Non-Executive Director and major...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced a...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce the recent publication of a joint effort fo...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today a...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today a...
Aptorum Group press release ( NASDAQ: APM ): 1H GAAP EPS of -$0.05. As of June 30, 2022, cash and restricted cash totalled approximately $7.2 million and total equity was approximately $15.6 million. Aptorum Group expects that its existing cash and restricted cash toge...
Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provid...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the commercial launch of NativusWell ...
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further updates on the analytical and both ...
News, Short Squeeze, Breakout and More Instantly...
Toronto, Ontario--(Newsfile Corp. - July 17, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) will report its second quarter 2024 financial and operating results after market close on Tuesday, August 13, 2024. Management will host a conference call...
Toronto, Ontario--(Newsfile Corp. - July 16, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) announced that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market making services, including use of its proprieta...
Toronto, Ontario--(Newsfile Corp. - July 11, 2024) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ( "Andean" or the "Company" ) is pleased to announce the appointment of Sylvain Lessard as President and General Manager of Golden Queen Mine, effective today, July 11, 2024. Wi...